4BB.L
4basebio PLC [4BB.L] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
4BB.L Stock Summary
Top 10 Correlated Stocks
4BB.L
In the News
4BB.L Financial details
Company Rating
-
Market Cap
130.61M
Income
-9.41M
Revenue
531K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
78
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-17.17
Forward P/E
-
PEG
-0.89
P/S
330.05
P/B
12.42
P/C
-
P/FCF
-13.31
Quick Ratio
2.9
Current Ratio
3.88
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.76
EPS next Y
-
EPS next Q
-
EPS this Y
61.54%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
100%
EPS Q/Q
107.14%
-
-
-
-
SMA20
-0.3%
SMA50
-0.74%
SMA100
-12.56%
Inst Own
-
Inst Trans
-
ROA
-44%
ROE
-55%
ROC
-0.57%
Gross Margin
89%
Oper. Margin
-2179%
Profit Margin
-1922%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
492.0-1020.0
52W High
+10.29%
52W Low
+128.66%
RSI
43.9
Rel Volume
0.05
Avg Volume
3.03K
Volume
138
Perf Week
0%
Perf Month
-2.17%
Perf Quarter
-11.76%
Perf Half Y
-16.67%
-
-
-
-
Beta
1.132
-
-
Volatility
0%, 22.83%
Prev Close
0%
Price
1125
Change
0%
Company Profile
- Volume Average 3.03K
- Market Capitalization 130.61M
- Employee 78
- CEO Dr. Heikki Lanckriet Ph.D.
- Headquarters Cambridge,GB
- IPO Date 2021-02-17
-
Website
https://www.4basebio.com 
4basebio PLC engages in the design, development, manufacturing, and supply of synthetic DNA and RNA products, and targeted non-viral vector solutions in the United States, Europe, and internationally. The company provides research kits, bulk enzymes, and other products, as well as licensing services; and AVV manufacturing services. It serves biotech, pharma, and contract development and manufacturing organization customers. The company was formerly known as 4basebio UK Societas and changed its name to 4basebio PLC in July 2021. 4basebio PLC was incorporated in 2020 and is based in Cambridge, United Kingdom.
